ArticleClinical rheumatology2025
Multiple comorbidities and economic burden of hospitalized gout patients in Guangdong Province.
Article in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The efficacy and safety of benzbromarone and febuxostat in combined-type hyperuricemia: a single-center study.Clinical rheumatology · 2026Article
- Factors associated with hyperuricemia in overweight or obese adults of Shenzhen, China.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionThis study aimed to analyze the prevalence of multiple comorbidities and economic burden of hospitalized patients with gout in Guangdong Province.
methodsWe retrieved the homepage information of 593,792 hospitalized patients with gout from January 1, 2015 to December 31, 2021 through the Guangdong Provincial Medical Record Homepage System and analyzed the prevalence of single comorbidity and multiple comorbidities and economic burden.
results1. The prevalence of gout was 1.31%. The prevalence in males was five times higher than that of females. 2. The prevalence of hypertension was highest (42.59%) in gout patients; the following were type 2 diabetes (18.03%) and hyperlipidemia (17.98%). 3. The prevalence of hypertension, hyperlipidemia, type 2 diabetes, chronic heart failure, coronary heart disease, and chronic kidney disease were more prevalent in women (P < 0.05). 4. Gout-hypertension-type 2 diabetes had the highest prevalence in all gout patients. The prevalence of multiple complications showed an increasing trend. 5. Gout- hypertension-type 2 diabetes had the highest prevalence in male and female patients (P < 0.001). Except for the prevalence of gout-hypertension-obesity, gout-obesity-type 2 diabetes and gout-hypertension-obesity-type 2 diabetes, the prevalence of other multiple comorbidities was significantly higher in women (P < 0.001). 6. The average annual cost of hospitalized patients with acute gouty arthritis ranged from RMB 5994.45 to RMB 6709.66, which decreased in women. From 2020 to 2021, the average cost of men with acute gout was much higher than that of women. From 2018 to 2021, the average cost was highest in patients among 40-69 years old.
conclusions1. Gout patients often have single and multiple comorbidities with a higher prevalence in women, and the prevalence showed an increasing trend. 2. Acute gout patients had high hospital costs, and female patients showed a downward trend. Key points • Gout patients have increasing single and multiple comorbidities with a higher prevalence in women. • Acute gout patients had high hospital costs, and female patients showed a downward trend.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.